Cargando…
Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis
BACKGROUND: Durvalumab is approved for the treatment of lung cancer, advanced biliary tract cancers, and is also being evaluated in many other solid organ tumors. The aim of our study is to define the incidence, etiology, and outcomes of liver injury in consecutive patients receiving durvalumab-base...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637844/ https://www.ncbi.nlm.nih.gov/pubmed/36353563 http://dx.doi.org/10.3389/fonc.2022.984940 |